A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.

ABSTRACT:

Background

The World Health Organisation (WHO) recommends that testing and treatment for latent tuberculosis infection (LTBI) should be undertaken in high-risk groups using either interferon gamma release assays (IGRAs) or a tuberculin skin test (TST). As IGRAs are more expensive than TST, an assessment of the cost-effectiveness of IGRAs can guide decision makers on the most appropriate choice of test for different high-risk populations. This current review aimed to provide the most up to date evidence on the cost-effectiveness evidence on LTBI testing in high-risk groups-specifically evidence reporting the costs per QALY of different testing strategies.

Methods

A comprehensive search of databases including MEDLINE, EMBASE and NHS-EED was undertaken from 2011 up to March 202

SUBMITTER: Mahon J 

PROVIDER: S-EPMC9533619 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature